Показано 0 из 0
Дата |
---|
03.05.2024 |
02.05.2024 |
01.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
22.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
8.19
|
9.00
|
8.88
|
8.56
|
9.05
|
8.56
|
|
|
53 749.19
|
117.00
|
8.28
|
8.87
|
8.65
|
8.65
|
8.77
|
8.65
|
|
|
85 953.78
|
167.00
|
8.20
|
9.68
|
7.86
|
7.81
|
8.67
|
8.59
|
|
|
152 474.46
|
217.00
|
7.09
|
7.98
|
7.56
|
7.49
|
7.83
|
7.74
|
|
|
59 903.86
|
217.00
|
7.22
|
7.92
|
7.45
|
7.44
|
7.81
|
7.67
|
|
|
117 217.83
|
238.00
|
7.15
|
8.17
|
7.39
|
7.21
|
7.43
|
7.30
|
|
|
31 527.02
|
123.00
|
7.19
|
8.17
|
7.30
|
7.07
|
7.32
|
7.29
|
|
|
41 834.26
|
188.00
|
6.95
|
8.17
|
7.26
|
7.14
|
7.48
|
7.38
|
|
|
39 772.63
|
122.00
|
6.13
|
7.49
|
7.12
|
7.045
|
7.40
|
7.235
|
|
|
96 431.48
|
318.00
|
6.13
|
8.17
|
6.82
|
6.82
|
7.24
|
7.14
|
|
|
242 542.12
|
276.00
|
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.